Tortus AI vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Eli Lilly leads in AI visibility (81 vs 35)
Tortus AI logo

Tortus AI

EmergingHealthcare

AI Clinical Documentation

Tortus AI provides an AI agent that sits alongside clinicians during patient visits, automatically generating clinical notes and handling documentation tasks in real time.

AI VisibilityBeta
Overall Score
D35
Category Rank
#551 of 596
AI Consensus
78%
Trend
stable
Per Platform
ChatGPT
32
Perplexity
29
Gemini
38

About

Tortus AI is a healthcare AI company founded in 2022 in London that develops an AI agent designed to reduce the documentation burden on physicians and clinical staff. The platform operates as a persistent AI presence during clinical encounters, listening to patient-clinician conversations and automatically generating structured clinical notes, coding suggestions, referral letters, and other administrative documentation. Unlike simple transcription tools, Tortus AI interprets clinical context to generate documentation that conforms to specialty-specific formats and coding requirements. The company serves NHS trusts and private healthcare organizations in the United Kingdom and is expanding internationally. Physician burnout driven by excessive documentation requirements is a critical healthcare workforce crisis, with doctors spending roughly half their working time on administrative tasks rather than patient care. Tortus AI addresses this directly by taking over documentation workflows and allowing clinicians to focus on clinical reasoning and patient relationships. The company raised $12M and has deployed across multiple clinical specialties including primary care, emergency medicine, and outpatient specialties with strong clinician satisfaction rates.

Full profile
Eli Lilly logo

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A81
Category Rank
#17 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
80
Perplexity
75
Gemini
77

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

35
Overall Score
81
#551
Category Rank
#17
78
AI Consensus
71
stable
Trend
stable
32
ChatGPT
80
29
Perplexity
75
38
Gemini
77
30
Claude
86
34
Grok
85

Key Details

Category
AI Clinical Documentation
General
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Tortus AI
AI Clinical Documentation

Integrations

Eli Lilly is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.